M. Gutierrez, G. Giaccone, H. Harper
May 20, 2015
Citations
0
Influential Citations
0
Citations
Quality indicators
Journal
Journal of Clinical Oncology
Abstract
e19033 Background: SNX-5422 is an orally bioavailable pro-drug of SNX-2112, a highly potent and selective Hsp90 inhibitor with preclinical anti-tumor activity in lung cancer models and synergy with platinum and taxane compounds. Carboplatin/paclitaxel is a commonly used treatment for advanced lung cancer. This phase 1 study examined SNX-5422 plus carboplatin/paclitaxel followed by SNX-5422 maintenance therapy in pts with advanced lung cancers. Methods: Eligible pts had advanced NSCLC (EGFR wild-type or non-sensitizing mutation, ALK wild-type) or extensive stage SCLC and up to one prior line of chemotherapy. Pts received paclitaxel (175 mg/m2) and carboplatin (AUC 5) q3w up to 4 courses and SNX-5422 qod (starting at 50 mg/m2), 21 of 28 days, with a standard 3+3 dose escalation rule during the combination followed by SNX-5422 (100 mg/m2 qod) monotherapy for maintenance until disease progression. Safety and tolerability were evaluated to determine the maximum tolerated dose (MTD) and pharmacokinetics of SNX-...